CA3249138A1 - ANTI-ILT3 ANTIBODIES AND THEIR USE - Google Patents

ANTI-ILT3 ANTIBODIES AND THEIR USE

Info

Publication number
CA3249138A1
CA3249138A1 CA3249138A CA3249138A CA3249138A1 CA 3249138 A1 CA3249138 A1 CA 3249138A1 CA 3249138 A CA3249138 A CA 3249138A CA 3249138 A CA3249138 A CA 3249138A CA 3249138 A1 CA3249138 A1 CA 3249138A1
Authority
CA
Canada
Prior art keywords
ilt3 antibodies
ilt3
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249138A
Other languages
English (en)
French (fr)
Inventor
Avidor Shulman
Ilana Mandel
Liat IANCOVICI
Motti Hakim
Tehila Ben-Moshe
Tsuri PERETZ
Yair Sapir
Yoav PIZEM
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of CA3249138A1 publication Critical patent/CA3249138A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3249138A 2022-04-25 2023-04-25 ANTI-ILT3 ANTIBODIES AND THEIR USE Pending CA3249138A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263334365P 2022-04-25 2022-04-25
US63/334,365 2022-04-25
PCT/IL2023/050426 WO2023209716A1 (en) 2022-04-25 2023-04-25 Anti-ilt3 antibodies and use thereof

Publications (1)

Publication Number Publication Date
CA3249138A1 true CA3249138A1 (en) 2023-11-02

Family

ID=86604937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249138A Pending CA3249138A1 (en) 2022-04-25 2023-04-25 ANTI-ILT3 ANTIBODIES AND THEIR USE

Country Status (9)

Country Link
US (1) US20250277032A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514472A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513588A (cg-RX-API-DMAC7.html)
KR (1) KR20250025354A (cg-RX-API-DMAC7.html)
CN (1) CN119487072A (cg-RX-API-DMAC7.html)
AU (1) AU2023258644A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249138A1 (cg-RX-API-DMAC7.html)
IL (1) IL316523A (cg-RX-API-DMAC7.html)
WO (1) WO2023209716A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4780848A1 (en) * 2023-09-20 2026-07-29 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
US9696312B2 (en) * 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
MA47468A (fr) * 2017-02-09 2019-12-18 Bluefin Biomedicine Inc Anticorps anti-ilt3 et conjugués anticorps-médicament
JP7194481B2 (ja) 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物3(ilt3)に特異的な抗体およびその使用
AU2019339469A1 (en) 2018-09-13 2021-03-11 Immune-Onc Therapeutics, Inc. Novel LILRB4 antibodies and uses thereof
EP3930756A4 (en) * 2019-03-01 2022-11-23 Board of Regents, The University of Texas System LILRB4 BINDING ANTIBODY AND METHODS OF USE THEREOF
NZ789331A (en) 2019-12-19 2026-02-27 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
CN115551894A (zh) * 2020-03-12 2022-12-30 以明生物免疫医疗公司 新型抗lilrb4抗体和衍生产物

Also Published As

Publication number Publication date
AU2023258644A1 (en) 2024-12-05
US20250277032A1 (en) 2025-09-04
JP2025513588A (ja) 2025-04-24
KR20250025354A (ko) 2025-02-21
IL316523A (en) 2024-12-01
EP4514472A1 (en) 2025-03-05
CN119487072A (zh) 2025-02-18
WO2023209716A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
EP4339208A4 (en) ANTI-TIGIT ANTIBODIES AND USE THEREOF
CA3265264A1 (en) CCR8 ANTIBODIES AND THEIR USES
CA3266237A1 (en) Anti-SARS-CoV-2 antibodies and their uses
CA3254156A1 (en) Anti-CD84 antibodies and their uses
CA3260932A1 (en) CD25-SPECIFIC ANTIBODIES AND THEIR USES
GB202303531D0 (en) Antibodies and uses thereof
CA3250007A1 (en) Anti-CD73 antibodies and their use
CA3305455A1 (en) B7-h3-binding antibody and use thereof
CA3255325A1 (en) Hla-g-specific antibody and use thereof
CA3291572A1 (en) Anti-fgfr2 antibody and use thereof
HK40126561A (en) Anti-cdh6 antibody and use thereof
HK40123272A (en) Antibody and use thereof
HK40121037A (en) Anti-ccr8 antibody and use thereof
CA3279528A1 (en) Anti-cd155 antibody and use thereof
CA3272657A1 (en) Anti-ccr8 antibody and use thereof
CA3268519A1 (en) Cd3-targeting antibody and use thereof
CA3262849A1 (en) Anti-ror1 antibody and use thereof
HK40117766A (en) Antibody and use thereof
HK40115076A (en) Anti-bdca2 antibody and use thereof
HK40115485A (en) Gprc5d antibody and use thereof
HK40109934A (en) Anti-cd73 antibody and use thereof
HK40113391A (en) Antibody and use thereof
HK40112387A (en) B7-h3-binding antibody and use thereof
HK40102274A (en) Anti-hla-g antibodies and use thereof
CA3299540A1 (en) Anti-b7-h3 antibodies and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241015

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S)

Effective date: 20241127

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241230

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250509

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250906

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250906

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250908

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260608